Developer docs
API playgroundTry for free, no card

Search company profiles

RheaVita

Full company profile

uuid0003e5o

Namestring
RheaVita
Legal namestring
RheaVita
Websiteurl
rheavita.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

RheaVita is a Belgian pharmaceutical technology company founded in 2018 and headquartered in Ghent, Belgium. It develops and commercializes continuous freeze-drying (lyophilization) equipment and process services for biologic, vaccine, and injectable drug manufacturers, with a customer base spanning large pharmaceutical companies (Sanofi, Pfizer, Bayer, GSK) and CDMOs/specialty service providers (Patheon/Thermo Fisher, Coriolis Pharma). The company's stated mission is to replace traditional batch lyophilization with a continuous, single-vial process that reduces cycle time and improves consistency for thermo-sensitive drug products.

The core platform, branded RheaLyo, combines spin-freezing, infrared heating, and real-time Process Analytical Technology (PAT) monitoring with computer-vision-based visual inspection and closed-loop process control. RheaVita offers a staged product line: the RheaLyo Mono system (R&D scale, with a BSL-2 compliant variant for biosafety-handled products), the RheaLyo Multi system (pre-clinical), and the GMP-Flex line for commercial cGMP manufacturing. The technology is protected by granted patents WO2013036107 and WO2018033468, with additional applications pending, and the company is engaged with FDA and EMA on the regulatory pathway for continuous lyophilization.

RheaVita's business model is a hybrid of capital equipment sales and process services. Equipment revenue is generated through direct sales to pharma and CDMO customers in Europe and the US and through distribution partners in Japan, Korea, and India. Service revenue comes from feasibility studies, stability batch production, and the Continuous Lyo Academy training program, which also functions as a market-development channel. Strategic OEM integration with IMA Life (2023) and CDMO adoption by Patheon/Thermo Fisher (2024-2025) are the principal go-to-market vehicles beyond direct sales. The company is backed by Novalis Biotech Acceleration and PMV following a EUR 2.5M Series A in June 2021.

Short descriptiontext

RheaVita is a Belgian pharmaceutical technology company developing continuous freeze-drying (lyophilization) equipment and process services for biologic drug manufacturers and CDMOs, using its proprietary RheaLyo platform with spin-freezing, infrared heating, and real-time PAT monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous freeze-drying, lyophilization equipment, biopharmaceutical manufacturing, spin-freeze drying, GMP freeze-dryers
Industry3 codes
PRIMARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SIC code1 code
  • Special Industry Machinery, Nec3559
Product category
Pharmaceutical Lyophilization Equipment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model7 records
1R&D Equipment Sales
TypeOne Time License
Description

Sale of RheaLyo Mono and RheaLyo Multi freeze-dryers for laboratory and pre-clinical use. Mono is single-vial unit for formulation development; Multi is larger version for stability batches with ~100 vials/day throughput.

rheavita.com
2GMP Equipment Sales
TypeOne Time License
Description

Sale of GMP-Flex freeze-dryers for clinical and commercial production. Only commercial GMP-compliant continuous freeze-drying system available, covering 100K to 2M vials annually. Pre-engineering studies offered for facility implementation planning.

3Feasibility Studies
TypeProfessional Services
Description

RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee. No CAPEX investment required from customers.

rheavita.com
4Stability Batch Production
TypeProfessional Services
Description

Outsource R&D freeze-drying using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality samples.

rheavita.com
5Continuous Lyo Academy Training
TypeProfessional Services
Description

Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered.

rheavita.com
6Lyo Recipe Development Services
TypeProfessional Services
Description

Process development and optimization services for customer formulations. Expert services charged by day fee with customized quotes.

knowledge.rheavita.com
7Formulation Development Services
TypeProfessional Services
Description

Full formulation development support for vaccines and biopharmaceuticals optimized for RheaLyo continuous freeze-drying process.

Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RheaLyo™
Description

Brand name for RheaVita's continuous freeze-drying technology platform, including RheaLyo Mono, RheaLyo Multi, and GMP-Flex product lines.

rheavita.com
+1 more record
Core offering1 text field

RheaVita develops, manufactures, and sells continuous freeze-drying (lyophilization) equipment for biopharmaceutical products based on its proprietary RheaLyo spin-freezing technology. The company offers a scalable portfolio of R&D freeze-dryers (RheaLyo Mono, RheaLyo Multi), GMP-compliant production lines (GMP-Flex series covering 100K–2M vials annually), and BSL-2 compliant variants, complemented by professional services including feasibility studies, contract stability batch production, formulation and recipe development, and training through the Continuous Lyo Academy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Drying time reduced by up to 40x (hours instead of days)
+5 more records
Product overview1 text field

RheaVita offers a scalable portfolio of continuous freeze-drying products centered on the RheaLyo™ technology platform. The RheaLyo™ Mono serves as the R&D cornerstone for rapid formulation and process development using single-vial units. The RheaLyo™ Multi is the larger pre-clinical version for stability batch production. The GMP-Flex lines represent the only commercial GMP-compliant continuous freeze-drying systems for clinical and commercial production, available in multiple capacity configurations (4/120, 16/240, 24/600). A BSL-2 compliant variant of the Mono is available for handling hazardous biological samples. All products share the core spin-freezing and infrared drying technology with PAT-enabled individual vial control, enabling direct scale-out from R&D to GMP with minimal tech transfer. Beyond equipment sales, RheaVita provides CDMO services including feasibility studies, stability batch production, and Continuous Lyo Academy training.

Product and service8 records
1RheaLyo Mono Freeze-Dryer
CategoryR&D Freeze-Drying Equipment
Description

R&D freeze-dryer for rapid formulation and process development. Single-vial unit enables ultra-fast continuous freeze-drying (hours instead of days) with minimal sample use. Designed for biopharmaceutical and formulation development scientists. Processes can be directly scaled to GMP production through the scale-out principle.

2RheaLyo Multi Freeze-Dryer
CategoryPre-Clinical Freeze-Drying Equipment
Description

Pre-clinical freeze-dryer designed for stability batch production. Features throughput of approximately 100 vials per day. Seamlessly scales from RheaLyo Mono recipes with minimal tech transfer to GMP production. Targeted at biopharma development teams needing larger stability batches than the Mono provides.

3RheaLyo GMP-Flex Lines
CategoryGMP Production Freeze-Drying Equipment
Description

GMP-compliant continuous freeze-drying system for clinical and commercial pharmaceutical production. Multiple configurations (4/120, 16/240, 24/600) covering 100,000 to 2 million vials annually. Features robotic automation in isolator conditions, CIP and SIP procedures, non-viable and viable particle monitoring, and documentation systems aligned with regulatory requirements. The only commercial GMP-compliant continuous freeze-drying system available.

4BSL-2 Compliant RheaLyo Mono Freeze-Dryer
CategoryR&D Freeze-Drying Equipment (Specialized)
Description

Specialized BSL-2 compliant variant of the RheaLyo Mono freeze-dryer for handling infectious biological materials. Features dedicated biosafety cabinet, HEPA-14 filtration (0.2 μm), ULPA filter on vacuum pump (0.1 μm), vertical laminar flow through HEPA filter, and compliance with EN 12469 biosafety standards. Add-on module for existing RheaLyo Mono systems.

5Feasibility Studies
CategoryProfessional Services
Description

Service where RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee with no CAPEX investment required from customers. Enables biopharma companies to evaluate continuous freeze-drying compatibility before committing to equipment purchases.

6Stability Batch Production
CategoryContract Manufacturing Services
Description

Outsourced R&D freeze-drying service using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality stability batch samples. Targeted at biopharma companies needing stability data without capital investment.

7Continuous Lyo Academy Training
CategoryTraining Services
Description

Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered online. Targeted at process engineers, formulation scientists, and operators in biopharmaceutical companies and CDMOs.

8Lyo Recipe Development and Formulation Development Services
CategoryProfessional Services
Description

Process development, optimization, and full formulation development services for customer biopharmaceutical formulations. Expert services charged by day fee with customized quotes. Targeted at biopharma companies developing vaccines, monoclonal antibodies, recombinant proteins, LNPs, AAVs, and peptides for continuous freeze-drying on RheaLyo systems.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Patheon Monza site installed RheaLyo Mono freeze-dryer as part of expansion of biopharma capabilities. Monza facility handles LNP formulation development, analytical services, and production of monoclonal antibodies and recombinant proteins. RheaVita technology integrated with Patheon's Pharmaceutical Development Services.

2IMA Life
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Strategic partnership to drive further technological development and commercial growth. IMA Life is a global provider of advanced aseptic pharmaceutical process and production solutions. Partnership announced with launch of BSL-2 compliant RheaLyo Mono freeze-dryer. IMA Life brings pharmaceutical equipment expertise and global commercial reach.

rheavita.com
3LyoHUB
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

RheaVita became formal member of LyoHUB, the Advanced Lyophilization Technology Hub. LyoHUB aims to advance science and technology of freeze-drying, identify best practices, conduct applied research, and disseminate knowledge. Membership aligns with RheaVita's continuous freeze-drying innovation.

rheavita.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding process concept originated from collaboration between RheaVita co-founders at Ghent University starting 2012. University provided research support for initial prototype development in 2018. Multiple PhDs and researchers from university have joined RheaVita team.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative relationship mentioned in context of RheaVita's commitment to advancing lyophilization science alongside partnerships with Ghent University and others.

6Reifycsanalytical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Japan market. Located in Osaka (Wakasugi building, Naktsu 1-18-18, Kita-ku). Handles sales and support of RheaVita products in Japan.

rheavita.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Korea market. Located in Seoul (Suite 402, Seodu Bldg, 25 Baumoe-ro 20-gil, Seocho-Gu). Handles sales and support of RheaVita products in Korea.

8Automed Systems P Ltd
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for India market. Located in Bangalore (9B, KIADB Electronic City Phase 2). Handles sales and support of RheaVita products in India.

rheavita.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global aseptic processing and pharmaceutical equipment leader, parent of Telstar, with a broad freeze-drying and fill-finish portfolio. Both RheaVita's flagship strategic partner and a potential competitor-developer of continuous lyophilization technology.

TypeBroad incumbent
Description

Major incumbent manufacturer of GMP lyophilization systems with deep installed base in pharma. Competes head-to-head with RheaVita's GMP-Flex lines for biopharma freeze-drying equipment budgets.

3SPX Technologies (formerly SPX FLOW)
TypeBroad incumbent
Description

Established pharmaceutical processing equipment provider with freeze-drying capabilities, serving large biopharma manufacturers globally. Overlaps with RheaVita in aseptic fill-finish and lyophilization equipment.

4Tofflon Science and Technology
TypeBroad incumbent
Description

Chinese-headquartered manufacturer of pharmaceutical equipment including freeze-dryers, aseptic filling lines, and isolators. Targets the same biopharma lyophilization equipment market as RheaVita with a broader portfolio.

TypeBroad incumbent
Description

German specialist in aseptic filling, closing, and freeze-drying systems for pharma and biotech. Provides GMP-compliant lyophilization equipment directly competing with RheaVita's GMP-Flex lines.

TypeDirect peer
Description

German engineering firm specializing in freeze-drying and lyophilization technology for pharmaceuticals, including continuous solutions. Direct competitor in continuous lyophilization development.

TypeEmerging player
Description

Specialist in closed-vial and aseptic fill-finish technology for injectable biologics. Adjacent competitor in the aseptic processing ecosystem relevant to RheaVita's freeze-drying customers.

TypeOthers
Description

Biologics formulation development CDMO that has integrated RheaVita's SVU technology. Functions as both customer and ecosystem partner in the continuous lyophilization space.

9Recipharm
TypeOthers
Description

Large CDMO offering lyophilization services across its manufacturing network. Represents both a potential customer for RheaLyo equipment and a downstream CDMO peer expanding into advanced biologics.

TypeOthers
Description

Provider of biopreservation and cold-chain solutions for cell and gene therapies. Adjacent to RheaVita's lyophilization offering in preserving high-value biologics and ATMPs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RheaVita

Pharmaceutical Lyophilization Equipmentrheavita.com

RheaVita is a Belgian pharmaceutical technology company developing continuous freeze-drying (lyophilization) equipment and process services for biologic drug manufacturers and CDMOs, using its proprietary RheaLyo platform with spin-freezing, infrared heating, and real-time PAT monitoring.

What RheaVita does

RheaVita is a Belgian pharmaceutical technology company founded in 2018 and headquartered in Ghent, Belgium. It develops and commercializes continuous freeze-drying (lyophilization) equipment and process services for biologic, vaccine, and injectable drug manufacturers, with a customer base spanning large pharmaceutical companies (Sanofi, Pfizer, Bayer, GSK) and CDMOs/specialty service providers (Patheon/Thermo Fisher, Coriolis Pharma). The company's stated mission is to replace traditional batch lyophilization with a continuous, single-vial process that reduces cycle time and improves consistency for thermo-sensitive drug products.

The core platform, branded RheaLyo, combines spin-freezing, infrared heating, and real-time Process Analytical Technology (PAT) monitoring with computer-vision-based visual inspection and closed-loop process control. RheaVita offers a staged product line: the RheaLyo Mono system (R&D scale, with a BSL-2 compliant variant for biosafety-handled products), the RheaLyo Multi system (pre-clinical), and the GMP-Flex line for commercial cGMP manufacturing. The technology is protected by granted patents WO2013036107 and WO2018033468, with additional applications pending, and the company is engaged with FDA and EMA on the regulatory pathway for continuous lyophilization.

RheaVita's business model is a hybrid of capital equipment sales and process services. Equipment revenue is generated through direct sales to pharma and CDMO customers in Europe and the US and through distribution partners in Japan, Korea, and India. Service revenue comes from feasibility studies, stability batch production, and the Continuous Lyo Academy training program, which also functions as a market-development channel. Strategic OEM integration with IMA Life (2023) and CDMO adoption by Patheon/Thermo Fisher (2024-2025) are the principal go-to-market vehicles beyond direct sales. The company is backed by Novalis Biotech Acceleration and PMV following a EUR 2.5M Series A in June 2021.

RheaVita firmographics

Firmographics
Name
RheaVita
Legal name
RheaVita
Website
https://rheavita.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
RheaVita is a Belgian pharmaceutical technology company developing continuous freeze-drying (lyophilization) equipment and process services for biologic drug manufacturers and CDMOs, using its proprietary RheaLyo platform with spin-freezing, infrared heating, and real-time PAT monitoring.
Ownership category
akta.pro rank

RheaVita industry classification

Industry
Product category
Pharmaceutical Lyophilization Equipment
SIC
Special Industry Machinery, Nec (3559)
akta.pro industry
PRIMARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Continuous freeze-drying
  • Lyophilization equipment
  • Biopharmaceutical manufacturing
  • Spin-freeze drying
  • GMP freeze-dryers

Where RheaVita is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

RheaVita business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. R&D Equipment Sales: Sale of RheaLyo Mono and RheaLyo Multi freeze-dryers for laboratory and pre-clinical use. Mono is single-vial unit for formulation development; Multi is larger version for stability batches with ~100 vials/day throughput.
  2. GMP Equipment Sales: Sale of GMP-Flex freeze-dryers for clinical and commercial production. Only commercial GMP-compliant continuous freeze-drying system available, covering 100K to 2M vials annually. Pre-engineering studies offered for facility implementation planning.
  3. Feasibility Studies: RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee. No CAPEX investment required from customers.
  4. Stability Batch Production: Outsource R&D freeze-drying using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality samples.
  5. Continuous Lyo Academy Training: Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered.
  6. Lyo Recipe Development Services: Process development and optimization services for customer formulations. Expert services charged by day fee with customized quotes.
  7. Formulation Development Services: Full formulation development support for vaccines and biopharmaceuticals optimized for RheaLyo continuous freeze-drying process.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

RheaVita product offering

Product offering

Core offering

RheaVita develops, manufactures, and sells continuous freeze-drying (lyophilization) equipment for biopharmaceutical products based on its proprietary RheaLyo spin-freezing technology. The company offers a scalable portfolio of R&D freeze-dryers (RheaLyo Mono, RheaLyo Multi), GMP-compliant production lines (GMP-Flex series covering 100K–2M vials annually), and BSL-2 compliant variants, complemented by professional services including feasibility studies, contract stability batch production, formulation and recipe development, and training through the Continuous Lyo Academy.

Product overview

RheaVita offers a scalable portfolio of continuous freeze-drying products centered on the RheaLyo™ technology platform. The RheaLyo™ Mono serves as the R&D cornerstone for rapid formulation and process development using single-vial units. The RheaLyo™ Multi is the larger pre-clinical version for stability batch production. The GMP-Flex lines represent the only commercial GMP-compliant continuous freeze-drying systems for clinical and commercial production, available in multiple capacity configurations (4/120, 16/240, 24/600). A BSL-2 compliant variant of the Mono is available for handling hazardous biological samples. All products share the core spin-freezing and infrared drying technology with PAT-enabled individual vial control, enabling direct scale-out from R&D to GMP with minimal tech transfer. Beyond equipment sales, RheaVita provides CDMO services including feasibility studies, stability batch production, and Continuous Lyo Academy training.

Differentiator

Problem solved

Functional benefit

Brands

  • RheaLyo™: Brand name for RheaVita's continuous freeze-drying technology platform, including RheaLyo Mono, RheaLyo Multi, and GMP-Flex product lines.
  • Continuous Lyo Academy

Products and services

  • RheaLyo Mono Freeze-Dryer R&D freeze-dryer for rapid formulation and process development. Single-vial unit enables ultra-fast continuous freeze-drying (hours instead of days) with minimal sample use. Designed for biopharmaceutical and formulation development scientists. Processes can be directly scaled to GMP production through the scale-out principle.
  • RheaLyo Multi Freeze-Dryer Pre-clinical freeze-dryer designed for stability batch production. Features throughput of approximately 100 vials per day. Seamlessly scales from RheaLyo Mono recipes with minimal tech transfer to GMP production. Targeted at biopharma development teams needing larger stability batches than the Mono provides.
  • RheaLyo GMP-Flex Lines GMP-compliant continuous freeze-drying system for clinical and commercial pharmaceutical production. Multiple configurations (4/120, 16/240, 24/600) covering 100,000 to 2 million vials annually. Features robotic automation in isolator conditions, CIP and SIP procedures, non-viable and viable particle monitoring, and documentation systems aligned with regulatory requirements. The only commercial GMP-compliant continuous freeze-drying system available.
  • BSL-2 Compliant RheaLyo Mono Freeze-Dryer Specialized BSL-2 compliant variant of the RheaLyo Mono freeze-dryer for handling infectious biological materials. Features dedicated biosafety cabinet, HEPA-14 filtration (0.2 μm), ULPA filter on vacuum pump (0.1 μm), vertical laminar flow through HEPA filter, and compliance with EN 12469 biosafety standards. Add-on module for existing RheaLyo Mono systems.
  • Feasibility Studies Service where RheaVita conducts feasibility studies demonstrating RheaLyo technology compatibility with customer formulations. Charged by day fee with no CAPEX investment required from customers. Enables biopharma companies to evaluate continuous freeze-drying compatibility before committing to equipment purchases.
  • Stability Batch Production Outsourced R&D freeze-drying service using GMP-Flex 250 equipment operating under non-GMP conditions. Customers avoid CAPEX investment and staff training while receiving high-quality stability batch samples. Targeted at biopharma companies needing stability data without capital investment.
  • Continuous Lyo Academy Training Training courses on freeze-drying fundamentals and advanced continuous spin freeze-drying technology. Courses held at RheaVita facilities or customer site. Free webinars also offered online. Targeted at process engineers, formulation scientists, and operators in biopharmaceutical companies and CDMOs.
  • Lyo Recipe Development and Formulation Development Services Process development, optimization, and full formulation development services for customer biopharmaceutical formulations. Expert services charged by day fee with customized quotes. Targeted at biopharma companies developing vaccines, monoclonal antibodies, recombinant proteins, LNPs, AAVs, and peptides for continuous freeze-drying on RheaLyo systems.

Quantifiable outcome

  • Drying time reduced by up to 40x (hours instead of days)
  • +5 more outcomes

Companies that use RheaVita

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

RheaVita technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

RheaVita partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship, minor and core.

  • Patheon (Thermo Fisher Scientific)flagshipTechnology or Integration · 1 January 2024Patheon Monza site installed RheaLyo Mono freeze-dryer as part of expansion of biopharma capabilities. Monza facility handles LNP formulation development, analytical services, and production of monoclonal antibodies and recombinant proteins. RheaVita technology integrated with Patheon's Pharmaceutical Development Services.
  • IMA LifeflagshipStrategic or Co-development Partner · 1 January 2023Strategic partnership to drive further technological development and commercial growth. IMA Life is a global provider of advanced aseptic pharmaceutical process and production solutions. Partnership announced with launch of BSL-2 compliant RheaLyo Mono freeze-dryer. IMA Life brings pharmaceutical equipment expertise and global commercial reach.
  • LyoHUBminorStrategic or Co-development Partner · 1 January 2023RheaVita became formal member of LyoHUB, the Advanced Lyophilization Technology Hub. LyoHUB aims to advance science and technology of freeze-drying, identify best practices, conduct applied research, and disseminate knowledge. Membership aligns with RheaVita's continuous freeze-drying innovation.
  • Ghent UniversitycoreStrategic or Co-development PartnerFounding process concept originated from collaboration between RheaVita co-founders at Ghent University starting 2012. University provided research support for initial prototype development in 2018. Multiple PhDs and researchers from university have joined RheaVita team.
  • CEPIminorStrategic or Co-development PartnerCollaborative relationship mentioned in context of RheaVita's commitment to advancing lyophilization science alongside partnerships with Ghent University and others.
  • Reifycsanalytical Co., Ltd.coreChannel Partner/ Reseller/ DistributorRegional distributor for Japan market. Located in Osaka (Wakasugi building, Naktsu 1-18-18, Kita-ku). Handles sales and support of RheaVita products in Japan.
  • Hahnson ImpexcoreChannel Partner/ Reseller/ DistributorRegional distributor for Korea market. Located in Seoul (Suite 402, Seodu Bldg, 25 Baumoe-ro 20-gil, Seocho-Gu). Handles sales and support of RheaVita products in Korea.
  • Automed Systems P LtdcoreChannel Partner/ Reseller/ DistributorRegional distributor for India market. Located in Bangalore (9B, KIADB Electronic City Phase 2). Handles sales and support of RheaVita products in India.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

RheaVita competitors and assessment

Company assessment

Broad incumbents

  • IMA Life: Global aseptic processing and pharmaceutical equipment leader, parent of Telstar, with a broad freeze-drying and fill-finish portfolio. Both RheaVita's flagship strategic partner and a potential competitor-developer of continuous lyophilization technology.
  • GEA Group: Major incumbent manufacturer of GMP lyophilization systems with deep installed base in pharma. Competes head-to-head with RheaVita's GMP-Flex lines for biopharma freeze-drying equipment budgets.
  • SPX Technologies (formerly SPX FLOW): Established pharmaceutical processing equipment provider with freeze-drying capabilities, serving large biopharma manufacturers globally. Overlaps with RheaVita in aseptic fill-finish and lyophilization equipment.
  • Tofflon Science and Technology: Chinese-headquartered manufacturer of pharmaceutical equipment including freeze-dryers, aseptic filling lines, and isolators. Targets the same biopharma lyophilization equipment market as RheaVita with a broader portfolio.
  • Optima Pharma: German specialist in aseptic filling, closing, and freeze-drying systems for pharma and biotech. Provides GMP-compliant lyophilization equipment directly competing with RheaVita's GMP-Flex lines.

Direct peers

  • HOF Sonderanlagenbau: German engineering firm specializing in freeze-drying and lyophilization technology for pharmaceuticals, including continuous solutions. Direct competitor in continuous lyophilization development.

Emerging players

  • Aseptic Technologies (AAT Bioquest): Specialist in closed-vial and aseptic fill-finish technology for injectable biologics. Adjacent competitor in the aseptic processing ecosystem relevant to RheaVita's freeze-drying customers.

Others

  • Coriolis Pharma: Biologics formulation development CDMO that has integrated RheaVita's SVU technology. Functions as both customer and ecosystem partner in the continuous lyophilization space.
  • Recipharm: Large CDMO offering lyophilization services across its manufacturing network. Represents both a potential customer for RheaLyo equipment and a downstream CDMO peer expanding into advanced biologics.
  • BioLife Solutions: Provider of biopreservation and cold-chain solutions for cell and gene therapies. Adjacent to RheaVita's lyophilization offering in preserving high-value biologics and ATMPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RheaVita social profiles

Digital presence

RheaVita compliance and trust

Trust signal

Compliance3 records

RheaVita financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RheaVita leadership team

Management profile

Number of profiles

Profiles11 records

RheaVita funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RheaVita M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RheaVita

What does RheaVita do?

RheaVita develops, manufactures, and sells continuous freeze-drying (lyophilization) equipment for biopharmaceutical products based on its proprietary RheaLyo spin-freezing technology. The company offers a scalable portfolio of R&D freeze-dryers (RheaLyo Mono, RheaLyo Multi), GMP-compliant production lines (GMP-Flex series covering 100K–2M vials annually), and BSL-2 compliant variants, complemented by professional services including feasibility studies, contract stability batch production, formulation and recipe development, and training through the Continuous Lyo Academy.

Is RheaVita a public or private company?

RheaVita is a private company. It is classified as venture growth investor backed and is currently operating.

When was RheaVita founded?

RheaVita was founded in 2018. It employs 11 to 50 people.

Where is RheaVita based?

RheaVita is headquartered in Ghent, Belgium, in the Europe region.

How does RheaVita make money?

Seven revenue lines are on record. R&D Equipment Sales are the primary driver. The others are GMP Equipment Sales, feasibility Studies, stability Batch Production, continuous Lyo Academy Training, lyo Recipe Development Services and formulation Development Services.

Who are RheaVita's main competitors?

Broad incumbents on record are IMA Life, GEA Group, SPX Technologies (formerly SPX FLOW), Tofflon Science and Technology and Optima Pharma. HOF Sonderanlagenbau is listed as a direct peer. Aseptic Technologies (AAT Bioquest) is listed as an emerging player. Others are Coriolis Pharma, Recipharm and BioLife Solutions.

Does RheaVita have an API?

No public API is recorded for RheaVita.

What industry is RheaVita in?

RheaVita's product category is Pharmaceutical Lyophilization Equipment. Its primary akta.pro industry code is HLAAAJAG, Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces), with a secondary code of HLAGABAI, Lyophilization (Freeze-Drying) CDMO. Its SIC code is 3559.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmTechINTERPHEX 2025: Continuous and Controlled Freeze-DryingRheaVita, a company providing continuous freeze-drying technology, is exhibiting at INTERPHEX 2025 in New York City, where CEO Thomas De Beer will present on GMP-ready continuous manufacturing. De Beer highlights that while regulatory uncertainty and industry hesitance pose challenges to innovation, existing guidelines have stimulated the shift from batch-wise to continuous manufacturing processes.Business Wire BlogRheaVita Announces Strategic Partnership With IMA Life, Part of the IMA Group, to Drive Further Technological Development and Commercial GrowthRheaVita announced a strategic partnership with IMA Life, which includes a financial investment and support for commercializing its continuous freeze-drying technology. The collaboration aims to expand market reach for biopharmaceutical production, targeting high-value, low-volume products like gene therapies and vaccines.FinSMEsRheaVita Raises €2.5M in Series A FundingRheaVita, a Ghent-based provider of freeze-drying technology for biopharmaceuticals, raised €2.5 million in Series A funding led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). The company plans to utilize the capital to build a GMP-compliant continuous freeze-drying production line and accelerate the commercialization of its technology.Business Wire BlogRheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMVRheaVita closed a EUR 2.5 million Series A financing co-led by Novalis Biotech Acceleration and PMV. The proceeds will build its first GMP-compliant continuous freeze-drying production line, scheduled to go live by end of 2021. The company will also accelerate commercialization and expand its team.AcrofanRheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMVRheaVita has closed a EUR 2.5 million Series A financing round co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV) to develop its continuous freeze-drying technology for biopharmaceuticals. This funding will support the installation of their first GMP compliant production line, scheduled to be operational by the end of 2021, and aid in accelerating commercialization efforts. The investment positions RheaVita to disrupt the traditional freeze-drying market by providing innovative solutions for biopharmaceutical production.BioSpaceRheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMVRheaVita has secured EUR 2.5 million in a Series A financing round co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). The funds will be used to establish the first GMP compliant production line for its innovative continuous freeze-drying technology, which is expected to be operational by the end of 2021. This technology aims to improve the production and delivery of biopharmaceutical products, addressing existing market challenges.